Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
28.77
+1.18 (4.28%)
Nov 11, 2025, 3:39 PM EST - Market open
Janux Therapeutics Revenue
Janux Therapeutics had revenue of $10.00M in the quarter ending September 30, 2025, with 2,177.90% growth. This brings the company's revenue in the last twelve months to $10.00M, down -23.37% year-over-year. In the year 2024, Janux Therapeutics had annual revenue of $10.59M with 30.99% growth.
Revenue (ttm)
$10.00M
Revenue Growth
-23.37%
P/S Ratio
167.32
Revenue / Employee
$123,457
Employees
81
Market Cap
1.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.59M | 2.51M | 30.99% |
| Dec 31, 2023 | 8.08M | -529.00K | -6.14% |
| Dec 31, 2022 | 8.61M | 4.98M | 136.79% |
| Dec 31, 2021 | 3.64M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JANX News
- 4 days ago - Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
- 3 months ago - Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
- 3 months ago - Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
- 4 months ago - Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - Business Wire
- 6 months ago - Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Business Wire
- 6 months ago - Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire